Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-186-4 | CAS number: 12125-02-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1983
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 983
- Report date:
- 1983
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- (10 animals/sex/dose)
- Principles of method if other than guideline:
- The study was conducted according to an internal BASF method whose principle is comparable to the OECD Guideline 401. A test group consisting of 10 animals/sex/dose was treated by single gavage with an aqueous solution of the test substance. Body weights were monitored during the 14 day observation period. The animals were observed for mortality and for clinical signs of toxicity for a period of 14 days. Decedents were subjected to necropsy. At the end of the observation period, the surviving animals were sacrificed (CO2 aphyxiation) for the purpose of necropsy. The LD50 value was estimated on the basis of the observed mortalities using the method of Finney D. J (Probit analysis, Cambridge University Press, 3 Aufl., 1971).
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Ammonium chloride
- EC Number:
- 235-186-4
- EC Name:
- Ammonium chloride
- Cas Number:
- 12125-02-9
- Molecular formula:
- ClH4N
- IUPAC Name:
- ammonium chloride
Constituent 1
- Specific details on test material used for the study:
- - Physical state: solid
- Analytical purity: 99.7%
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr.K.THOMAE GmbH, Biberach, Germany
- Weight at study initiation: male: 170-178 g, female: 171-187 g (within 20% of mean weight)
- Fasting period before study: The animals were given no feed for 16 hours before administration, but water was available ad libitum
- Housing: 5 animals per cage (Type VII A steel cages; FA Becker & Co., Castrop-Rauxel)
- Diet: Kliba-Labordiaet, (Klingentalmuehle AG, CH); ad libitum
- Water: tap water; ad libitum
- Acclimation period: for at least one week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20- 24
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- - Concentration of test substance in vehicle: 6.81, 10, 14.7, 21.5 %
- Maximum Volume applied: 10 mL/kg bw - Doses:
- 681, 1000, 1470, 1780, 2150 mg/kg bw
- No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations: several times on the day of administration, at least once each workday. Check for mortality and moribund animals was performed twice daily on week days and once daily on Saturday, Sunday or on public holidays.
- Frequency of weighing: days 0, 3, 4, 7, 9, 13
- Necropsy of survivors performed: yes; before sacrifice, animals were fasted for a period of 16 hours
- Other examinations performed: clinical signs, body weight, histopathology
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 1 410 mg/kg bw
- Based on:
- dissolved
- Remarks:
- in water
- 95% CL:
- >= 1 260 - <= 1 550
- Remarks on result:
- other: Slope factor = 1.36
- Mortality:
- Mortality: (out of 10 males and 10 females)
- Number of dead males at doses 2150, 1780, 1470, 1000 and 681: (after 1h) 8/7/4/0/0, (after 1d) 8/7/4/0/0, (≥2-14d) 8/7/4/0/0
- Number of dead females at doses, 2150, 1780, 1470, 1000, 681: (after 1h) 10/9/7/0/0, (after 1d) 10/9/7/3/0, (≥2-14d) 10/9/7/3/0 - Clinical signs:
- other: No clinical signs were manifested by animals of the lowest dose group (NOEL clinical signs = 681 mg/kg bw). Clinical signs were seen in animals dosed with 1000 mg/kg bw and above. Clinical symptoms indicated an influence on the central nervous system. Fo
- Gross pathology:
- Dying animals:
- General congestion: poor
- Heart: dilatation bilaterally; sporadically dilatation on the left side;
- Stomach: atonic; liquid contents; malacia of the mucosa in the glandular stomach;
- Intestines: atonic, diarrheal and mucous contents; malacia of the mucosa in several cases; - Other findings:
- Histopathology (only one animal):
- Liver: fatty degeneration
- Kidney: fatty degeneration, lower nephron nephrosis
Any other information on results incl. tables
Table 1: Mortality
Dose (mg/kg bw) |
Conc. |
Gender |
1 h |
24 h |
48 h |
day 7 |
day 14 |
2150 |
21.5 |
male |
8 |
8 |
8 |
8 |
8 |
female |
10 |
10 |
10 |
10 |
10 |
||
1780 |
17.8 |
male |
7 |
7 |
7 |
7 |
7 |
female |
9 |
9 |
9 |
9 |
9 |
||
1470 |
14.7
|
male |
4 |
4 |
4 |
4 |
4 |
female |
7 |
7 |
7 |
7 |
7 |
||
1000 |
10.0 |
male |
0 |
0 |
0 |
0 |
0 |
female |
0 |
3 |
3 |
3 |
3 |
||
681 |
6.81 |
male |
0 |
0 |
0 |
0 |
0 |
female |
0 |
0 |
0 |
0 |
0 |
Table 2: Weight (g)
Dose (mg/kg bw) |
Gender |
day 0 |
day 3/4 |
day 7 |
day 9 |
day 13 |
2150 |
male |
178 |
216 |
248 |
262 |
- |
female |
178 |
- |
- |
- |
- |
|
1780 |
male |
171 |
206 |
236 |
245 |
- |
female |
179 |
198 |
210 |
219 |
- |
|
1470 |
male |
170 |
210 |
241 |
251 |
- |
female |
179 |
204 |
220 |
221 |
- |
|
1000 |
male |
177 |
226 |
246 |
- |
283 |
female |
179 |
207 |
213 |
- |
226 |
|
681 |
male |
170 |
221 |
240 |
- |
269 |
female |
171 |
205 |
210 |
- |
218 |
Table 3: Clinical signs
Dose (mg/kg bw) |
2150 |
1780 |
1470 |
1000 |
681 |
|||||
|
male |
female |
male |
female |
male |
female |
male |
female |
male |
female |
Dyspnea |
<15 m-5 h |
<15 m-30 m |
<15 m-5 h |
<15 m-5 h |
<15 m-5 h |
<15 m-5 h |
15 m-2 h |
15 m-2 h |
- |
- |
Apathy |
<15 m-1 h |
<15 m-30 m |
<15 m-1 h |
<15 m-1 h |
<15 m-1 h |
<15 m-1 h |
30 m-2 h |
30 m-2 h |
- |
- |
Abnormal position |
<15 m-1 h |
<15 m-30 m |
15 m-30 m |
15 m-1 h |
30 m |
15 m-30 m |
- |
30 m |
- |
- |
Stagger |
1 h-5 h |
- |
<15 m-5 h |
<15 m-5 h |
<15 m-5 h |
<15m-5 h |
15 m-2 h |
15 m-2 h |
- |
- |
Atony |
<15 m-30 m |
<15 m-30 m |
15 m-30 m |
15 m-1 h |
30 m |
30 m |
- |
- |
- |
- |
Twitching |
<15 m-1 h |
<15 m-30 m |
15 m-1 h |
15 m-1 h |
30 m-1 h |
15 m-1 h |
- |
30 m |
- |
- |
Tonic convulsions |
15 m-30 m |
15 m-30 m |
- |
30 m |
- |
- |
- |
- |
- |
- |
Piloerection |
4 h-5 h |
- |
4 h-5 h |
4 h-5 h |
4 h-5 h |
4 h-5 h |
- |
- |
- |
- |
Exophthalmus |
<15 m-1 h |
<15 m-30 m |
15 m-1 h |
15 m-1 h |
30 m-1 h |
15 m-1 h |
- |
- |
- |
- |
Poor general state |
<15 m-1 h |
<15 m-30 m |
<15 m-1 h |
<15 m-1 h |
<15 m-1 h |
<15 m-1 h |
30 m-2 h |
30 m-2 h |
- |
- |
m: minutes
h: hour
d: day
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.